Full text

Turn on search term navigation

© 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

ABSTRACT

We investigated the influence of CYP2B6, GSTP1, and SLCO1B1 star allele‐predicted phenotypes and CBR1 variants on clinical outcomes in patients with HCC receiving DOX via TACE. A prospective cohort of patients with HCC underwent DOX therapy via TACE. Selected genes were genotyped in germline DNA samples from the final cohort (82 patients) via Axiom Precision Medicine Diversity (PMD) Research Array technology. The Kaplan–Meier (KM) method and Cox proportional hazards (CPH) model were employed to find independent clinical and genetic predictors of overall survival (OS) and progression‐free survival (PFS) after TACE. Based on univariate and combined association analyses of genetic factors, the star alleles predicting the phenotypic status of three genes (CYP2B6, GSTP1, and SLCO1B1) did not significantly modify the response potential of DOX via TACE, as indicated by OS or PFS. Conversely, we found a novel association between two CBR1 polymorphisms (rs3787728 and rs1005695) and interindividual differences in OS and PFS. The presence of a heterozygous genotype (TC or CG at either locus, which were highly frequent in our cohort), probably with greater CBR metabolic activity, appeared to have an expressive influence by negatively modulating the consequences of DOX locoregional therapy on HCC by shortening the median OS (KM p = 0.02 and 0.04, respectively) and median PFS (KM p = 0.05 and 0.023, respectively) in comparison to those with other haplotypes. Exploratory PGx studies involving a wider HCC cohort and targeting more DOX‐related genes are needed to replicate our findings.

Trial Registration: NCT06313047 (Study Details | Pharmacogenetic of Doxorubicin in HCC. | clinicaltrials.gov)

Details

Title
The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele‐Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization
Author
Shilbayeh, Sireen Abdul Rahim 1   VIAFID ORCID Logo  ; Abd El‐Baset, Omnia A. 2 ; Alshabeeb, Mohammad A. 3   VIAFID ORCID Logo  ; Alanizi, Abdalrhman Hamdan 4   VIAFID ORCID Logo  ; Khedr, Naglaa F. 5   VIAFID ORCID Logo  ; Werida, Rehab H. 6   VIAFID ORCID Logo 

 Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia 
 Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt 
 King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU‐HS), Ministry of National Guard Health, Riyadh, Saudi Arabia 
 Department of Pharmaceutical Care Services, Medical Affairs, King Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia 
 Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt 
 Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt 
Section
ORIGINAL ARTICLE
Publication year
2025
Publication date
Jun 1, 2025
Publisher
John Wiley & Sons, Inc.
e-ISSN
20521707
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3219206439
Copyright
© 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.